A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors

NCT07124793 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

Interventions

DRUG: IBI363+IBI305

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.